Agios Pharm Market Cap ($1.82 Billion)
Market Cap & Net Worth: Agios Pharm (AGIO)
Agios Pharm market cap. Agios Pharm (NASDAQ:AGIO) has a market capitalization of $1.82 Billion ($1.82 Billion) as of October 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6223 globally and #2006 in its home market, demonstrating a -17.85% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Agios Pharm's stock price $30.55 by its total outstanding shares 59701882 (59.70 Million).
Agios Pharm Market Cap History (2015–2026)
Agios Pharm market cap history from 2015 to 2026. Data shows change from $3.88 Billion to $1.82 Billion (-7.02% CAGR). Check Agios Pharm (AGIO) stock price for real-time trading data and today's change.
Index Memberships
Agios Pharm is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Dow Jones Biotechnology
DJUSBT
|
$1.15 Trillion | 0.16% | #19 of 39 |
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.07% | #178 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.00% | #705 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.10% | #107 of 263 |
Weight: Agios Pharm's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Agios Pharm Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Agios Pharm's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see AGIO operating cash flow for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
30.08x
Agios Pharm's market cap is 30.08 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.49 Billion | $69.89 Million | -$198.47 Million | 35.65x | N/A |
| 2017 | $3.41 Billion | $43.01 Million | -$314.67 Million | 79.36x | N/A |
| 2018 | $2.75 Billion | $94.39 Million | -$346.03 Million | 29.17x | N/A |
| 2019 | $2.85 Billion | $117.91 Million | -$411.47 Million | 24.18x | N/A |
| 2020 | $2.59 Billion | $203.20 Million | -$327.37 Million | 12.73x | N/A |
| 2021 | $1.96 Billion | $41.41K | $1.60 Billion | 47390.68x | 1.22x |
| 2022 | $1.68 Billion | $14.24 Million | -$231.80 Million | 117.73x | N/A |
| 2023 | $1.33 Billion | $26.82 Million | -$352.09 Million | 49.57x | N/A |
| 2024 | $1.96 Billion | $36.50 Million | $673.73 Million | 53.75x | 2.91x |
| 2025 | $1.63 Billion | $54.03 Million | -$412.78 Million | 30.08x | N/A |
Competitor Companies of AGIO by Market Capitalization
Companies near Agios Pharm in the global market cap rankings as of October 31, 2026. See Agios Pharm balance sheet quality to understand what proportion of total assets are financed by equity.
Key companies related to Agios Pharm by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Agios Pharm (2015–2026)
Market capitalization of Agios Pharm from 2015 to today. Between 2015 and today, Agios Pharm's market cap moved from $3.88 Billion to $ 1.82 Billion, with a yearly change of -7.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.82 Billion | +12.23% |
| 2025 | $1.63 Billion | -17.16% |
| 2024 | $1.96 Billion | +47.55% |
| 2023 | $1.33 Billion | -20.69% |
| 2022 | $1.68 Billion | -14.57% |
| 2021 | $1.96 Billion | -24.14% |
| 2020 | $2.59 Billion | -9.26% |
| 2019 | $2.85 Billion | +3.56% |
| 2018 | $2.75 Billion | -19.35% |
| 2017 | $3.41 Billion | +37.00% |
| 2016 | $2.49 Billion | -35.72% |
| 2015 | $3.88 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Agios Pharm was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.82 Billion USD |
| MoneyControl | $1.82 Billion USD |
| MarketWatch | $1.82 Billion USD |
| marketcap.company | $1.82 Billion USD |
| Reuters | $1.82 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Agios Pharm
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment… Read more